ArticleLasers in medical science2026
Evaluation of the efficacy of oral propranolol combined with pulsed dye laser versus monotherapy with oral propranolol in the treatment of mixed infantile hemangiomas.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Oral propranolol is first-line for problematic infantile hemangiomas (IHs) but often leaves superficial residual lesions. This study assessed the efficacy and safety of adding pulsed dye laser (PDL) to propranolol versus propranolol alone for mixed IHs. This single-center retrospective cohort study included children with mixed IHs treated from January 2020 to September 2024, assigned to oral propranolol alone or with PDL. VESS (Vascular Density, Color Intensity, Texture Change) scores at 3 months, Achauer grade ≥ 4 at 1, 3, and 6 months, and regression metrics at 6 months were measured. Safety, parent-reported outcomes, treatment duration, and 12-month sequelae were also recorded. A total of 247 children were included (132 propranolol, 115 combination). The combination group had lower VESS scores at 3 months (all P < 0.010). Achauer grade ≥ 4 was more frequent at all time points (40.87% vs. 22.73% at 1 month, P = 0.002). Area reduction (75.66% vs. 70.75%, P < 0.001), thickness reduction (P = 0.024), and colorimetric ΔE (P = 0.003) were greater. Superficial erythema resolution improved (P = 0.002) with similar deep mass volume reduction. Satisfaction with color improvement (P < 0.001) and quality of life (P < 0.001), and shorter treatment duration (5.79 vs. 6.55 months, P = 0.007) favored the combined group. Recurrence (2.61% vs. 9.85%, P = 0.041) and residual telangiectasia (5.22% vs. 12.88%, P = 0.039) were lower. Transient purpura occurred only with PDL (22.61% vs. 0%, P < 0.001); other events were comparable. Adding PDL to oral propranolol significantly improves superficial clearance and aesthetic outcomes, accelerates global improvement, and reduces long-term recurrence and residual telangiectasia in mixed IHs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.